TCRX – tscan therapeutics, inc. (US:NASDAQ)
Stock Stats
News
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
TScan Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $11.00 price target on the stock.
TScan Therapeutics GAAP EPS of -$0.25, revenue of $1.04M Nov. 12, 2024 9:48 AM ET By: Urvi Shah , SA News Editor [Seeking Alpha]
TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Form 8-K TScan Therapeutics, Inc. For: Nov 15
Form 4 TScan Therapeutics, Inc. For: Nov 15 Filed by: Nichols Weston
Form SC 13G/A TScan Therapeutics, Inc. Filed by: BIOTECHNOLOGY VALUE FUND L P
Form SC 13G/A TScan Therapeutics, Inc. Filed by: K2 HealthVentures Equity Trust LLC
Form SC 13G/A TScan Therapeutics, Inc. Filed by: Cormorant Asset Management, LP
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.